Bio-Techne (TECH) Other Non-Current Assets (2010 - 2026)
Bio-Techne (TECH) posted quarterly Other Non-Current Assets of $264.4 million for Q1 2026, down 1.72% year-over-year from $269.0 million in Q1 2025, and down 1.02% quarter-over-quarter from $267.1 million in Q4 2025.
Bio-Techne (TECH) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Bio-Techne's Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $264.4 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 1.72% year-over-year to $264.4 million; the TTM figure through Mar 2026 stood at $264.4 million (down 1.72% YoY), while the FY2025 annual figure was $12.3 million, down 95.33% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $264.4 million, down from $267.1 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $285.3 million in Q2 2023, with the low at $1.0 million in Q4 2024.
- The 5-year median for Other Non-Current Assets is $53.9 million (2022), against an average of $145.1 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets plunged 96.64% in 2024, then soared 25409.46% in 2025.
- Bio-Techne's Other Non-Current Assets stood at $53.2 million in 2022, then slumped by 49.91% to $26.6 million in 2023, then tumbled by 96.07% to $1.0 million in 2024, then jumped by 25409.46% to $267.1 million in 2025, then decreased by 1.02% to $264.4 million in 2026.
- Business Quant data shows TECH's Other Non-Current Assets at $264.4 million in Q1 2026, $267.1 million in Q4 2025, and $276.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Bio-Techne | 11.33 Bn | 11.12 Bn | 208.29 Mn | 264.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 264.37 Mn |
| Dec 31, 2025 | 267.08 Mn |
| Sep 30, 2025 | 276.56 Mn |
| Jun 30, 2025 | 12.33 Mn |
| Mar 31, 2025 | 268.99 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | 9.46 Mn |
| Jun 30, 2024 | 264.27 Mn |
| Mar 31, 2024 | 26.67 Mn |
| Dec 31, 2023 | 26.65 Mn |
| Sep 30, 2023 | 281.58 Mn |
| Jun 30, 2023 | 285.30 Mn |
| Mar 31, 2023 | 283.35 Mn |
| Dec 31, 2022 | 53.19 Mn |
| Sep 30, 2022 | 53.90 Mn |
| Jun 30, 2022 | 46.83 Mn |
| Mar 31, 2022 | 45.98 Mn |
| Dec 31, 2021 | 37.11 Mn |
| Sep 30, 2021 | 11.59 Mn |
| Jun 30, 2021 | 11.58 Mn |